Mining TCGA database for genes of prognostic value in glioblastoma microenvironment
- PMID: 29676997
- PMCID: PMC5940130
- DOI: 10.18632/aging.101415
Mining TCGA database for genes of prognostic value in glioblastoma microenvironment
Abstract
Glioblastoma (GBM) is one of the most deadly brain tumors. The convenient access to The Cancer Genome Atlas (TCGA) database allows for large-scale global gene expression profiling and database mining for potential correlation between genes and overall survival of a variety of malignancies including GBM. Previous reports have shown that tumor microenvironment cells and the extent of infiltrating immune and stromal cells in tumors contribute significantly to prognosis. Immune scores and stromal scores calculated based on the ESTIMATE algorithm could facilitate the quantification of the immune and stromal components in a tumor. To better understand the effects of genes involved in immune and stromal cells on prognosis, we categorized GBM cases in the TCGA database according to their immune/stromal scores into high and low score groups, and identified differentially expressed genes whose expression was significantly associated with prognosis in GBM patients. Functional enrichment analysis and protein-protein interaction networks further showed that these genes mainly participated in immune response, extracellular matrix, and cell adhesion. Finally, we validated these genes in an independent GBM cohort from the Chinese Glioma Genome Atlas (CGGA). Thus, we obtained a list of tumor microenvironment-related genes that predict poor outcomes in GBM patients.
Keywords: CGGA; TCGA; immune scores; overall survival; tumor microenvironment.
Conflict of interest statement
Figures







Similar articles
-
Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.J Cell Physiol. 2021 Jan;236(1):507-522. doi: 10.1002/jcp.29878. Epub 2020 Jun 22. J Cell Physiol. 2021. PMID: 32572951
-
Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.World Neurosurg. 2019 Dec;132:e76-e88. doi: 10.1016/j.wneu.2019.08.253. Epub 2019 Sep 10. World Neurosurg. 2019. PMID: 31518750
-
Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas.Front Immunol. 2020 Oct 20;11:585034. doi: 10.3389/fimmu.2020.585034. eCollection 2020. Front Immunol. 2020. PMID: 33193404 Free PMC article.
-
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.Front Immunol. 2020 Jul 17;11:1402. doi: 10.3389/fimmu.2020.01402. eCollection 2020. Front Immunol. 2020. PMID: 32765498 Free PMC article. Review.
-
The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.Mol Cell Endocrinol. 2017 Aug 15;451:53-65. doi: 10.1016/j.mce.2017.01.004. Epub 2017 Jan 12. Mol Cell Endocrinol. 2017. PMID: 28089821 Review.
Cited by
-
Bioinformatic Profiling of Prognosis-Related Genes in Malignant Glioma Microenvironment.Med Sci Monit. 2020 Aug 26;26:e924054. doi: 10.12659/MSM.924054. Med Sci Monit. 2020. PMID: 32843610 Free PMC article.
-
Identification of biomarkers related to tumorigenesis and prognosis in breast cancer.Gland Surg. 2022 Sep;11(9):1472-1488. doi: 10.21037/gs-22-449. Gland Surg. 2022. PMID: 36221277 Free PMC article.
-
Identification of P2RY13 as an immune-related prognostic biomarker in lung adenocarcinoma: A public database-based retrospective study.PeerJ. 2021 May 5;9:e11319. doi: 10.7717/peerj.11319. eCollection 2021. PeerJ. 2021. PMID: 33996281 Free PMC article.
-
Bioinformatics analysis of SH2D4A in glioblastoma multiforme to evaluate immune features and predict prognosis.Transl Cancer Res. 2024 Aug 31;13(8):4242-4256. doi: 10.21037/tcr-23-2000. Epub 2024 Aug 23. Transl Cancer Res. 2024. PMID: 39262462 Free PMC article.
-
Prognostic Implications of Novel Gene Signatures in Gastric Cancer Microenvironment.Med Sci Monit. 2020 Aug 2;26:e924604. doi: 10.12659/MSM.924604. Med Sci Monit. 2020. PMID: 32740646 Free PMC article.
References
-
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, et al., and European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, and National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987–96. 10.1056/NEJMoa043330 - DOI - PubMed
-
- Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, et al., and Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017; 376:1027–37. 10.1056/NEJMoa1611977 - DOI - PubMed
-
- Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, et al., and Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17:98–110. 10.1016/j.ccr.2009.12.020 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical